Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Healthcare is changing done AI and personalized compartment therapy. Which of these high-growth innovators represents the amended risk-adjusted accidental for your portfolio contiguous arsenic you measure Heartflow Inc. (NASDAQ:HTFL) and Iovance Biotherapeutics (NASDAQ:IOVA)?

Heartflow focuses connected non-invasive AI diagnostics for bosom disease, portion Iovance develops personalized compartment therapies to dainty coagulated tumors. Both companies are scaling commercialized operations successful high-stakes aesculapian fields, offering investors vulnerability to cutting-edge objective technology. This examination evaluates their fiscal wellness and marketplace risks to find which aligns champion with your concern strategy.

The lawsuit for Heartflow Inc.

Heartflow sells AI-enabled bundle designed to analyse coronary artery disease. The institution provides these tools to clinicians to assistance place blockages much accurately than accepted tests. Heartflow presently maintains astir 1,465 accounts successful the U.S. and is expanding its scope among healthcare stocks by focusing connected its halfway FFR CT Analysis product, which generates astir 98% of its revenue.

In FY 2025, gross reached astir $176 million, a 40% summation implicit the anterior year. Despite this beardown top-line expansion, the concern reported a nett nonaccomplishment of $116.8 cardinal for the period.

As of its December 2025 equilibrium sheet, the debt-to-equity ratio is astir 0.1x. This ratio compares full indebtedness to shareholders' equity, indicating a debased level of borrowing comparative to shareholders' equity. Free currency flow, calculated arsenic currency from operations minus superior expenditures, was astir antagonistic $59.0 cardinal for the year.

The lawsuit for Iovance Biotherapeutics

Iovance Biotherapeutics develops personalized tumor-infiltrating lymphocyte therapies to dainty patients with cancer. The institution generates gross by selling its superior products, Amtagvi and Proleukin, to hospitals, clinics, and specialized distributors. To enactment its pipeline, Iovance maintains captious licence agreements with large organizations, including Novartis AG (NYSE:NVS) and Cellectis SA (NASDAQ:CLLS), while operating its ain centralized manufacturing facility.

During FY 2025, the institution reported gross of $263.5 million, reflecting a important 60.6% maturation complaint implicit the anterior year. This summation followed the palmy commercialized scaling of its pb therapies crossed North American markets. However, the institution recorded a nett nonaccomplishment of astir $391 million, somewhat deeper than 2024.

According to its December 2025 equilibrium sheet, Iovance maintains a debt-to-equity ratio of astir 0.1x. Free currency travel for fiscal twelvemonth 2025 was antagonistic $336.2 million, reflecting the dense superior requirements of personalized compartment therapy manufacturing and objective trials.